Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Nassir Ghaemi, Tufts Medical Center
ClinicalTrials.gov Identifier:
NCT00562861
First received: November 20, 2007
Last updated: June 11, 2013
Last verified: June 2013
  Purpose

Bipolar depression is one of the least studied depressive illnesses. The standard practice for many doctors is to use antidepressant medicines, but there are few studies on the long-term results of these medicines. The goal of this study is to look at how effective and safe these medicines are in treating bipolar depression when taken with a mood stabilizer medicine.

The drug being studied is citalopram, also known as Celexa. Celexa is FDA approved for the treatment of major depression, but is not FDA approved for the treatment of bipolar depression. It is, however, standard practice for many doctors is to use antidepressants, like Celexa, to treat their patients with bipolar disorder depression.

The drug will be studied in three ways. We will see if it helps treat depressive symptoms. We will see how the drug affects the brain using PET and fMRI scans. Finally, we will look at the possibility that there may be a gene that could predict if a person would get better taking the drug using genetics.


Condition Intervention Phase
Bipolar Disorder
Bipolar Depression
Drug: citalopram + mood stabilizer
Procedure: FDG PET scans
Procedure: MRI structural scans
Procedure: Genotyping
Procedure: Blood Draw
Drug: placebo + mood stabilizer
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram

Resource links provided by NLM:


Further study details as provided by Tufts Medical Center:

Primary Outcome Measures:
  • In acute treatment, citalopram will be more effective than placebo for depressive symptoms in bipolar disorder [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • In acute treatment, citalopram will be associated with a greater risk of acute hypomania, mixed-states, or mania than placebo. [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
  • In maintenance treatment, the total number of affective episodes and their rate (episodes/study time), as well as time to intervention with other medications and time to first episode, will be lower in the placebo than in the citalopram group. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Antidepressant response or remission in depressed bipolar patients will be associated with changes in cortical and paralimbic regions, consistent with SRI antidepressant response in unipolar depressed patients. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Polymorphic variation at the 5HTTLPR gene will alter the risk of acute mania or increased mood-cycling with citalopram vs. placebo treatments [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: November 2007
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Mood stabilizer plus citalopram
Drug: citalopram + mood stabilizer
Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
Other Name: Celexa
Procedure: FDG PET scans
Two scans will be acquired in two separate PET imaging sessions, 6 weeks apart (baseline vs. end-of-acute treatment phase). The exploratory imaging component of this study will be limited to 60 individuals (30 in each arm) taking lithium as a sole mood stabilizer.
Procedure: MRI structural scans

MRI acquisitions will be acquired using a Siemens 3T whole body scanner (Trio) with a 60 cm diameter bore.

Anatomical imaging will be conducted for anatomic reference for precise spatial normalization of co-registered PET images for the planned functional analyses.

The exploratory imaging component of this study will be limited to 60 individuals (30 in each arm) taking lithium as a sole mood stabilizer.

Procedure: Genotyping
Subjects will be asked to provide a blood sample at the start of the study and after 6 weeks for the genotyping portion of the study.
Procedure: Blood Draw
Subjects will have their blood drawn at Tufts Medical Center at the same time as their safety labs are performed.
Placebo Comparator: 2
Mood stabilizer alone
Procedure: FDG PET scans
Two scans will be acquired in two separate PET imaging sessions, 6 weeks apart (baseline vs. end-of-acute treatment phase). The exploratory imaging component of this study will be limited to 60 individuals (30 in each arm) taking lithium as a sole mood stabilizer.
Procedure: MRI structural scans

MRI acquisitions will be acquired using a Siemens 3T whole body scanner (Trio) with a 60 cm diameter bore.

Anatomical imaging will be conducted for anatomic reference for precise spatial normalization of co-registered PET images for the planned functional analyses.

The exploratory imaging component of this study will be limited to 60 individuals (30 in each arm) taking lithium as a sole mood stabilizer.

Procedure: Genotyping
Subjects will be asked to provide a blood sample at the start of the study and after 6 weeks for the genotyping portion of the study.
Procedure: Blood Draw
Subjects will have their blood drawn at Tufts Medical Center at the same time as their safety labs are performed.
Drug: placebo + mood stabilizer
This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
Other Name: lithium, lamotrigine, valproate, or carbamazepine

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Current age ≥18 years
  • DSM-IV diagnosis of BPD, type-I, or type-II
  • Current major depressive episode using DSM-IV criteria, lasting 8 weeks or longer.
  • Use of lithium, divalproex, carbamazepine, or lamotrigine at therapeutic serum levels or doses for ≥4 weeks prior to study entry, or willingness to accept one of these agents.
  • Prior to initial evaluations, each subject must provide competent, written, informed consent.

Exclusion Criteria:

  • Past non-response to a therapeutic trial of R,S-citalopram (≥100 mg/day for ≥8 weeks).
  • Previous intolerance of R,S-citalopram;
  • Diagnosis of unipolar depression
  • Diagnosis of schizoaffective disorder
  • Serious medical illness with acute instability (cardiac, respiratory, hepatic, renal), based on hospitalization in the past month
  • Abnormal thyroid function tests
  • Previous allergic reaction to or inability to tolerate lithium, divalproex, or carbamazepine at therapeutic serum levels.
  • Current or past renal dysfunction if taking lithium
  • Current or past hepatitis or other liver disease if taking divalproex
  • Current or past hematologic disease if on carbamazepine
  • Severe suicidal ideation, plan or intent, as documented by a score of ≥4 on the Montgomery Åsberg Depression Rating Scale suicidality item (Item 10).
  • Presence of psychosis
  • Cognitive impairment sufficient to impair ability to give informed consent.
  • Current pregnancy, or inability to utilize contraception
  • The presence of any metallic implants
  • History of claustrophobia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00562861

Locations
United States, Georgia
Emory University School of Medicine: Wesley Woods Health Center
Atlanta, Georgia, United States, 30322
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, North Carolina
Duke University School of Medicine
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Tufts Medical Center
Investigators
Principal Investigator: Nassir Ghaemi, MD, MPH Tufts University Medical
  More Information

No publications provided

Responsible Party: Nassir Ghaemi, Director of Mood Disorders Program, Tufts Medical Center
ClinicalTrials.gov Identifier: NCT00562861     History of Changes
Other Study ID Numbers: MH78060-01A1, MH-0708060-01
Study First Received: November 20, 2007
Last Updated: June 11, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Tufts Medical Center:
Bipolar Disorder
Bipolar Depression
Clinical Trials, Phase II
Clinical Pharmacology

Additional relevant MeSH terms:
Bipolar Disorder
Depression
Depressive Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Behavioral Symptoms
Citalopram
Dexetimide
Valproic Acid
Carbamazepine
Lithium
Lamotrigine
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on July 26, 2014